Nyxoah S.A. (NASDAQ:NYXH) Given Average Recommendation of “Moderate Buy” by Analysts

Nyxoah S.A. (NASDAQ:NYXH) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $17.80.

NYXH has been the topic of several recent analyst reports. Cantor Fitzgerald dropped their target price on Nyxoah from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, May 15th. Stifel Nicolaus dropped their price objective on Nyxoah from $27.00 to $19.00 and set a “buy” rating on the stock in a report on Monday. HC Wainwright decreased their target price on Nyxoah from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, May 24th. Oppenheimer dropped their price target on shares of Nyxoah from $20.00 to $15.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 15th. Finally, Piper Sandler boosted their price objective on shares of Nyxoah from $15.00 to $20.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th.

Nyxoah Price Performance

Shares of NYXH opened at $7.95 on Wednesday. The company has a quick ratio of 3.70, a current ratio of 3.94 and a debt-to-equity ratio of 0.13. Nyxoah has a fifty-two week low of $4.00 and a fifty-two week high of $20.00. The firm’s 50 day moving average price is $9.29 and its 200 day moving average price is $9.81.

Nyxoah (NASDAQ:NYXH) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.45) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.45). The business had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.20 million. Nyxoah had a negative return on equity of 42.14% and a negative net margin of 843.49%. As a group, analysts predict that Nyxoah will post -1.69 EPS for the current fiscal year.

Institutional Trading of Nyxoah

An institutional investor recently bought a new position in Nyxoah stock. Iron Triangle Partners LP acquired a new position in shares of Nyxoah S.A. (NASDAQ:NYXH) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 253,025 shares of the company’s stock, valued at approximately $3,413,000. Nyxoah accounts for about 0.3% of Iron Triangle Partners LP’s portfolio, making the stock its 28th largest position.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.